









Markets
/
Stocks
/
nasdaq-aimd
/

Ainos Inc

AIMD

3.760USD

+0.250+7.12%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

16.05MMarket Cap

LossP/E TTM



Ainos Inc

3.760

+0.250+7.12%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

229 / 506

Overall Ranking

369 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.

Growing

The company is in a growing phase, with the latest annual income totaling USD 20.73K.

Undervalued

The company’s latest PE is -1.49, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 2.94M shares, increasing 14.84% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 270.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.38.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.47, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.47

Change



Financials

4.73

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.21

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.86

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.39, which is -76.41% below the recent high of -0.33 and 41.54% above the recent low of -0.81.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 229/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.19, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 4.04 and the support level at 3.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.19

Change

0.42

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.077

Neutral

RSI(14)

58.621

Neutral

STOCH(KDJ)(9,3,3)

61.908

Buy

ATR(14)

0.257

Low Volatility

CCI(14)

115.174

Buy

Williams %R

11.927

Overbought

TRIX(12,20)

0.247

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

3.509

Buy

MA10

3.516

Buy

MA20

3.639

Buy

MA50

3.223

Buy

MA100

2.093

Buy

MA200

1.324

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 70.16%, representing a quarter-over-quarter increase of 8.77%. The largest institutional shareholder is The Vanguard, holding a total of 270.00 shares, representing 0.01% of shares outstanding, with 55.12% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Taiwan Carbon Nano Technology Corp

1.09M

-0.54%

Ainos Inc

491.26K

Lee (Ting Chuan)

465.71K

+62.67%

Tsai (Chun-Hsien)

330.37K

+119.70%

Tsai (Chun-Jung)

277.00K

-3.00%

Lee (Hsin Liang Christopher)

55.27K

+947.87%

chang (wen-han)

51.55K

+139.23%

chiang (yao-chung)

41.28K

+265.96%

Wei (Pao- Sheng)

40.88K

+275.74%

Tsai (Chung-Yi)

40.88K

+275.74%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.90, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.29. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.